Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Development of Non-invasive Protocol
Interventions: ethanol dilution; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Graft Versus Host Disease, Hematologic Neoplasms
Interventions: Busulfan, Fludarabine, Cyclophosphamide, Mycophenolate Mofetil, Sirolimus; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tendinosis, Tendinitis
Interventions: Tenotomy (no injection), Ultrasound guided platelet rich plasma injection; Procedure · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Injury of Body of Pancreas
Interventions: Secretin, Placebo; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Medication Absorption
Interventions: Water, Parmalat™ Whole Milk, Similac Pro-Advance™, Ensure Plus™, Furosemide 20 MG; Dietary Supplement · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hydrocephalus
Interventions: Not listed
Lead sponsor: Transonic Systems Inc.; Industry
Eligibility: Up to 20 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Intracranial Hemorrhage, Ventriculitis, Intracranial Abscess
Interventions: IRRAflow® CNS (Active Fluid Exchange) System; Device
Lead sponsor: Christopher P Kellner; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Polycystic Kidney, Autosomal Recessive
Interventions: Tesevatinib; Drug
Lead sponsor: Kadmon Corporation, LLC; Industry
Eligibility: 5 Years to 12 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Milwaukee, Wisconsin

Conditions: Respiratory Syncytial Virus
Interventions: mRNA-1345, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 10,994 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 109
States / cities: Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 93 more

Conditions: Wound Infection Due to Staphylococcus Aureus, MRSA Infection of Postoperative Wound
Interventions: antiseptic bundle, standard of care; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Neovascular (Wet) Age-Related Macular Degeneration
Interventions: aflibercept, High-dose aflibercept; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 45
States / cities: Phoenix, Arizona • Sun City, Arizona • Encino, California + 42 more

Conditions: Adenoid Cystic Carcinoma
Interventions: Lenvatinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Dysphagia
Interventions: Proactive pharyngeal-laryngeal Exercise Program, Premier Protein Clear ® High Protein, Hydration Counseling; Behavioral · Dietary Supplement
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 99 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Polypoidal Choroidal Vasculopathy
Interventions: ranibizumab intravitreal injection; Drug
Lead sponsor: Hawaii Pacific Health; Other
Eligibility: 25 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Honolulu, Hawaii • ‘Aiea, Hawaii

Conditions: Fetal Growth Abnormality, Amniotic Fluid; Disorder
Interventions: Point-of-care ultrasound (POC-US), Routine antenatal care, Formal ultrasound; Diagnostic Test
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Familial Cancer, BRCA1-Associated Protein-1 (BAP1) Mutations, Tumor Predisposition Syndrome (TPDS), Mesothelioma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 30 Years to 120 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2038
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Migraine
Interventions: Omega 3 Polyunsaturated Fats, Matching Placebo; Dietary Supplement · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 10 Years to 17 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Kidney Injury
Interventions: Data Inclusion; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 200,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Breast Cancer
Interventions: MRI, Lumbar puncture; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: JNJ-38431055, Sitagliptin 100 mg, JNJ-38431055 + Sitagliptin 100 mg, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Blunt Trauma, Penetrating Wound, Hemorrhagic Shock
Interventions: 0.9% Sodium Chloride 250 mL bolus, 0.9% Sodium Chloride 2000 mL bolus; Drug
Lead sponsor: University of Washington; Other
Eligibility: 15 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Birmingham, Alabama • Portland, Oregon • Pittsburgh, Pennsylvania + 2 more

Conditions: Primary Sclerosing Cholangitis
Interventions: oral vancomycin and oral amoxicillin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 76 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Gastrointestinal, Colic
Interventions: Lactobacillus reuteri, Placebo; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 3 Weeks to 3 Months
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pneumococcal Vaccine
Interventions: MVX01, MVX01 Placebo; Biological
Lead sponsor: Matrivax Research and Development Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Savannah, Georgia • Knoxville, Tennessee

Search by objective public record fields.

Fluid Volume During Fluid Shifts

Optimizing PTCy Dose and Timing

A Prospective Comparison of Ultrasound-Guided Percutaneous Platelet-Rich Plasma Injection

Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection

Evaluating Predictive Methods & Product Performance in Healthy Adults for Pediatric Patients, A Case Study: Furosemide

Monitoring Patient Cerebro-Spinal Fluid Drainage With an Ultrasonic Flow Sensor

Clearance of Intracranial Blood Products by Continuous Irrigation With the IRRAflow System

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

S. Aureus Screening and Decolonization

Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma

Anterior Cervical Discectomy and Fusion (ACDF) - Behavioral Intervention

Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)

Serial Third Trimester Abdominal Circumference and Amniotic Fluid Measurements Versus Routine Care

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

Omega-3 Supplementation for Pediatric Migraine

I USE LR in the ED

Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin

Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma

Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC

Safety and Effect of L. Reuteri on Biomarkers of Inflammation in Healthy Infants With Colic

A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine